Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer

Fig. 3

PPP2R5E and BCL2L11 are direct targets of miR-19b. a Luciferase reporter assay of PC9 cells transduced with pre-miR19b (pmiR19b), pre-control (pmiRscr), anti-miR19b (αmiR19b) and anti-control (αscr) and transfected with constructs containing the wild-type (TS) or mutated (mTS) miR-19b target site from PPP2R5E or BCL2L11, respectively. Luciferase activity is presented as mean ± SD relative to Renilla activity (n = 3). b PPP2R5E and BCL2L11 mRNA levels by real-time qPCR in anti-miR19b–transduced NSCLC cells. Results are presented as mean fold change relative to the control ±SD, normalized to GAPDH (n = 3). c Western blot analysis of pre-miR-19b and anti-miR19b–transduced NSCLC cells using PPP2R5E and BCL2L11 specific antibodies. Protein levels were normalized to α-tubulin and GAPDH and presented relative to the control. d PP2A activity assay of pre-miR19b- and anti-miR19b–transduced cells relative to the control (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001

Back to article page